Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.49 |
| ▸ | HTR2C | P28335 | 8/20 | 0.49 |
| ▸ | HTR2B | P41595 | 8/20 | 0.49 |
| ▸ | PNMT | P11086 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396030 | 0.85 | CCNB2 (0.46) | HTR2AHTR2CHTR2BPNMTLMNA | |
| SCHEMBL675760 | 0.85 | CCNB2 (0.46) | HTR2AHTR2CHTR2BPNMTLMNA | |
| SCHEMBL10792005 | 0.84 | NQO2 (0.45) | LMNAPOLBTDP1ATMALDH1A1 | |
| SCHEMBL28340616 | 0.79 | DYRK1A (0.46) | HTR2CHTR2BPNMT | |
| SCHEMBL5022472 | 0.79 | PNMT (0.59) | HTR2AHTR2CHTR2BPNMTALDH1A1 | |
| SCHEMBL6223597 | 0.77 | HTR2A (0.50) | HTR2AHTR2CHTR2BLMNAPOLB | |
| SCHEMBL11162952 | 0.77 | HTR2C (0.58) | HTR2AHTR2CHTR2BLMNAATM | |
| SCHEMBL13365442 | 0.77 | ADCY6 (0.44) | PNMT | |
| SCHEMBL3882991 | 0.76 | PNMT (0.48) | HTR2AHTR2CHTR2BPNMTLMNA | |
| SCHEMBL329913 | 0.76 | HTR2A (0.61) | HTR2AHTR2CHTR2BPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053878-A1 | PROCESS FOR EXTRACTION OF ACTIVE COMPOUNDS FROM PLANT BIOMASS | NEURAL THERAPEUTICS INC (CA) | 2026-02-26 | — | — | US | disclosed |
| US-12551519-B2 | Extraction system and method for organic metabolites | VCENNA TECH & LABS INC (CA) | 2026-02-17 | — | — | US | disclosed |
| US-20250339631-A1 | CONTROLLED RELEASE OF SUBSTANCES FROM A SOURCE MATERIAL STORED OVER TIME | SYQE MEDICAL LTD. (IL) | 2025-11-06 | — | — | US | disclosed |
| US-20250162980-A1 | METHODS FOR PREPARING MESCALINE | JOURNEY COLAB CORP. | 2025-05-22 | — | — | US | disclosed |
| US-20250157614-A1 | SUBSTANCE DELIVERY PLANNING SYSTEM | SYQE MEDICAL LTD. (IL) | 2025-05-15 | — | — | US | disclosed |
| EP-4504308-A1 | CONTROLLED RELEASE OF SUBSTANCES FROM A SOURCE MATERIAL STORED OVER TIME | Syqe Medical Ltd. (IL) | 2025-02-12 | — | — | EP | disclosed |
| US-20240245632-A1 | METHODS OF TREATING SUBSTANCE USE DISORDERS USING MESCALINE | JOURNEY COLAB CORP. | 2024-07-25 | — | — | US | disclosed |
| US-20240123005-A1 | EXTRACTION SYSTEM AND METHOD FOR ORGANIC METABOLITES | Etminan, Seyed Reza (CA) | 2024-04-18 | — | — | US | disclosed |
| US-20240108577-A1 | CONTROLLED RELEASE OF SUBSTANCES FROM A SOURCE MATERIAL | SYQE MEDICAL LTD. (IL) | 2024-04-04 | — | — | US | disclosed |
| WO-2024040358-A1 | PROCESS FOR EXTRACTION OF ACTIVE COMPOUNDS FROM PLANT BIOMASS | NEURAL THERAPEUTICS INC. (CA) | 2024-02-29 | — | — | WO | disclosed |
| EP-0569380-B1 | ACRIDINE DERIVATIVES | GLAXO LAB SA (FR) | 1997-05-28 | — | — | EP | disclosed |
| US-5604237-A | IMPROVE OR INCREASE EFFICACY OF ANTITUMOR AGENT, INCREASE OR RESTORE SENSITIVITY OF TUMOR TO ANTITUMOR AGENT, REVERSE OR REDUCE RESISTANCE OF TUMOR TO ANTITUMOR AGENT | LABORATOIRES GLAXO SA (FR) | 1997-02-18 | — | — | US | disclosed |
| US-5561141-A | POTENTIATE ACTIVITY OF ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY (US) | 1996-10-01 | — | — | US | disclosed |
| US-5550149-A | SULFUR-CONTAINING COMPOUNDS THAT ARE EFFECTIVE IN POTENTIATING THE ACTIVITY OF CHEMOTHERAPEUTIC ANTI-CANCER AGENTS BY INCREASING SENSITIVITY OF MULTI-DRUG RESISTANT CELLS | AMERICAN CYANAMID COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| CN-1114650-A | MDR reversal agents | AMERICAN CYANAMID CO (US) | 1996-01-10 | — | — | CN | disclosed |
| US-5387685-A | MDR reversal agents | AMERICAN CYANAMID COMPANY | 1995-02-07 | — | — | US | disclosed |
| EP-0634401-A1 | MDR reversal agents | AMERICAN CYANAMID COMPANY (US) | 1995-01-18 | — | — | EP | disclosed |
| EP-0569380-A1 | ACRIDINE DERIVATIVES. | GLAXO LAB SA (FR) | 1993-11-18 | — | — | EP | disclosed |
| WO-1992012132-A1 | ACRIDINE DERIVATIVES | LABORATOIRES GLAXO S.A. (FR) | 1992-07-23 | — | — | WO | disclosed |
| EP-0494623-A1 | Acridine derivatives | LABORATOIRES GLAXO SA (FR) | 1992-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053878-A1 | PROCESS FOR EXTRACTION OF ACTIVE COMPOUNDS FROM PLANT BIOMASS | CARM1, CLK4, NPM1 | HTR2A 4528/4885HTR2C 4575/4885HTR2B 4689/4885 |
| US-20240245632-A1 | METHODS OF TREATING SUBSTANCE USE DISORDERS USING MESCALINE | SLC6A12, SLC6A3, TPMT | HTR2A 93/4885HTR2C 24/4885HTR2B 246/4885 |
| US-20250162980-A1 | METHODS FOR PREPARING MESCALINE | IL4I1, ME3, LIG3 | HTR2A 3249/4885HTR2C 2131/4885HTR2B 2009/4885 |
| US-12551519-B2 | Extraction system and method for organic metabolites | SHH, WNT1, WNT3A | HTR2A 319/4885HTR2C 42/4885HTR2B 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.